In the initial preclinical study of LLY-283 as a radiosensitizer described here, a single dose reduced tumor sDMA levels for at least 24 h, indicating the effective targeting of PRMT5 under in vivo conditions. This evidence concerns the gene PRMT5 and neoplasm.